Pipeline Update: Four IPOs on the schedule for next week Source Cluster: IPO Boutique Source Node: 3095511Time Stamp: Feb 2, 2024
The Week’s 10 Biggest Funding Rounds: Generate Capital Goes Big Again, Kore.ai Nabs $150M Source Cluster: Crunchbase News Source Node: 3095526Time Stamp: Feb 2, 2024
The Week’s 10 Biggest Funding Rounds: Recurrent Energy And Bilt Rewards See Big Money Source Cluster: Crunchbase News Source Node: 3086944Time Stamp: Jan 26, 2024
BD, Hamilton Collaborate to Standardize Single-Cell Multiomics Experiments Using Robotics | BioSpace Source Cluster: BioSpace Source Node: 3083142Time Stamp: Jan 22, 2024
Pipeline Update: Four IPOs on the Schedule; Filings trickle in Source Cluster: IPO Boutique Source Node: 3072222Time Stamp: Jan 19, 2024
Pipeline Update: Biotech filings highlight week of 1/12/24 Source Cluster: IPO Boutique Source Node: 3059090Time Stamp: Jan 12, 2024
SeaStar Medical Appoints David A. Green as Chief Financial Officer | BioSpace Source Cluster: BioSpace Source Node: 3059839Time Stamp: Jan 10, 2024
Aelis Farma Announces Completion of Patient Randomization for Phase 2b Study with AEF0117 for the Treatment of Cannabis Addiction – Medical Marijuana Program Connection Source Cluster: MMPConnect Source Node: 3052666Time Stamp: Jan 9, 2024
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum Source Cluster: Fintech News Source Node: 3049508Time Stamp: Jan 5, 2024
Pipeline Update: New Filings & Terms Added (Ending 01.05.24pm) Source Cluster: IPO Boutique Source Node: 3058769Time Stamp: Jan 5, 2024
Carbon Prices and Voluntary Carbon Markets Faced Major Declines in 2023, What’s Next for 2024? Source Cluster: Carbon Credits News Source Node: 3044774Time Stamp: Jan 3, 2024
Delivering responsible AI in the healthcare and life sciences industry – IBM Blog Source Cluster: IBM Source Node: 3045055Time Stamp: Jan 3, 2024
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) – Medical Marijuana Program Connection Source Cluster: MMPConnect Source Node: 3042645Time Stamp: Jan 2, 2024
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors | BioSpace Source Cluster: BioSpace Source Node: 3038279Time Stamp: Dec 26, 2023
Modernize your ETL platform with AWS Glue Studio: A case study from BMS | Amazon Web Services Source Cluster: AWS Big Data Source Node: 3012623Time Stamp: Dec 13, 2023
Median Technologies Announces Rebranding of iBiopsy®, Changes Name to eyonis™ Source Cluster: Fintech News Source Node: 2980567Time Stamp: Nov 26, 2023
Biopharma Company FibroBiologics to go Public Through Direct Listing on Nasdaq | SPAC Feed Source Cluster: SPAC Feed Source Node: 2970277Time Stamp: Nov 10, 2023
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of September 30th, 2023 Source Cluster: Fintech News Source Node: 2921847Time Stamp: Oct 6, 2023
Scientists Unearth Brand New Links Between Genes and Disease in Our Blood Source Cluster: Singularity Hub Source Node: 2921685Time Stamp: Oct 6, 2023
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023 – Medical Marijuana Program Connection Source Cluster: MMPConnect Source Node: 2916801Time Stamp: Oct 4, 2023